Autopsy report · NCT01330589

Pharmacodynamic Study on Efficacy of Clopidogrel With St. John's Wort

“Inability to enroll subjects and changes in standard of care for PCI”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

Lancaster General Hospital

Sponsor type

University, hospital or other

Conditions

Acute Coronary Syndrome

Interventions

Placebo; St. Johns Wort

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
  “evolving standard of care and difficulties of enrolling participants” (62% match in meaning)
• Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
  “Lack of enrollment and changing landscape of standard of care.” (58% match in meaning)
• Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease
  “due to the difficulty to enroll suitable patients” (57% match in meaning)
• Wellness Initiative at New York University
  “Due to inability to enroll patients” (57% match in meaning)
• Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement
  “Unable to enroll appropriate patients” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.